Group 1 - The core point of the article is that TuoJing Life (SZ 300642) announced a board meeting to discuss changes to its registered address and amendments to its articles of association [1] - The meeting was held on November 11, 2025, via teleconference in Shanghai [1] - TuoJing Life's revenue composition for the year 2024 is entirely from the in vitro diagnostics industry, accounting for 100.0% [1] Group 2 - As of the report, TuoJing Life has a market capitalization of 3.4 billion yuan [1]

Core Viewpoint - The company, Beijing Saikexide Technology Co., Ltd., focuses on the research, development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis, aiming to provide automated testing solutions for medical institutions [7][28]. Company Overview - The company has established a core technology cluster covering instruments, reagents, and consumables, with five major technology categories including blood rheology measurement technology and coagulation diagnostic testing technology [25][28]. - The company has 45 patents, including 14 invention patents, and has received multiple awards for its technological advancements [26]. Business Model - The company operates on a "self-research and production, sales-driven production, and mainly distribution" model, which aligns with industry practices and its development stage [9][14]. - The procurement model is based on "production-driven ordering," ensuring quality through long-term partnerships with qualified suppliers [10]. - The production model is "sales-driven production," allowing for adjustments based on market conditions and inventory [11]. Industry Analysis - The in vitro diagnostic market in China has shown a compound annual growth rate (CAGR) of 18.6% from 2014 to 2018, with the market size exceeding 100 billion RMB in 2021 [16]. - The thrombosis and hemostasis in vitro diagnostic market is in a rapid development phase, with a CAGR of 24.8% from 2015 to 2019 [16]. - The demand for coagulation testing is expected to grow due to factors such as population aging and advancements in medical technology, despite a temporary slowdown from 2020 to 2022 [16]. Technological Trends - The industry is characterized by high technical content and rapid growth, with a significant focus on innovation and new product development [17][18]. - The clinical application of thrombosis and hemostasis testing is evolving towards disease prevention, diagnosis, and drug monitoring, driven by advancements in direct oral anticoagulants (DOACs) [29][30]. Financial Highlights - The company plans to distribute a cash dividend of 3.3 RMB per 10 shares, totaling approximately 34.31 million RMB, which represents 30.36% of the net profit attributable to shareholders [4][5].